Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Saha K
,
Partilla JS
,
Lehner KR
,
Seddik A
,
Stockner T
,
Holy M
,
Sandtner W
,
Ecker GF
,
Sitte HH
,
Baumann MH
.
???displayArticle.abstract???
The nonmedical use of synthetic cathinones is increasing on a global scale. 4-Methyl-N-methylcathinone (mephedrone) is a popular synthetic cathinone that is now illegal in the United States and other countries. Since the legislative ban on mephedrone, a number of 'second-generation' analogs have appeared in the street drug marketplace, including 4-methyl-N-ethylcathinone (4-MEC) and 4'-methyl-α-pyrrolidinopropiophenone (4-MePPP). Here we characterized the interactions of 4-MEC and 4-MePPP with transporters for 5-HT (SERT) and dopamine (DAT) using molecular, cellular, and whole-animal methods. In vitro transporter assays revealed that 4-MEC displays unusual 'hybrid' activity as a SERT substrate (ie, 5-HT releaser) and DAT blocker, whereas 4-MePPP is a blocker at both transporters but more potent at DAT. In vivo microdialysis experiments in rat brain demonstrated that 4-MEC (1-3 mg/kg, i.v.) produced large increases in extracellular 5-HT, small increases in dopamine, and minimal motor stimulation. In contrast, 4-MePPP (1-3 mg/kg, i.v.) produced selective increases in dopamine and robust motor stimulation. Consistent with its activity as a SERT substrate, 4-MEC evoked inward current in SERT-expressing Xenopus oocytes, whereas 4-MePPP was inactive in this regard. To examine drug-transporter interactions at the molecular level, we modeled the fit of 4-MEC and 4-MePPP into the binding pockets for DAT and SERT. Subtle distinctions in ligand-transporter binding were found that account for the differential effects of 4-MEC and 4-MePPP at SERT. Collectively, our results provide key information about the pharmacology of newly emerging mephedrone analogs, and give clues to structural requirements that govern drug selectivity at DAT vs SERT.
Aarde,
Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats.
2013, Pubmed
Aarde,
Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats.
2013,
Pubmed
Aarde,
The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats.
2013,
Pubmed
Adams,
Ionic currents in the human serotonin transporter reveal inconsistencies in the alternating access hypothesis.
2003,
Pubmed
,
Xenbase
Andersen,
Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter.
2010,
Pubmed
Ayres,
A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public (ill)health. Legal highs or illegal highs?
2012,
Pubmed
Baumann,
Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.
2013,
Pubmed
Baumann,
In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat.
2011,
Pubmed
Baumann,
The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.
2012,
Pubmed
Baumann,
Psychoactive "bath salts": not so soothing.
2013,
Pubmed
Baumann,
Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates.
2014,
Pubmed
,
Xenbase
Blough,
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
2014,
Pubmed
Bonano,
Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats.
2014,
Pubmed
Brandt,
Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones.
2011,
Pubmed
Cameron,
Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.
2013,
Pubmed
,
Xenbase
Carroll,
Bupropion and bupropion analogs as treatments for CNS disorders.
2014,
Pubmed
Cercato,
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
2009,
Pubmed
Dargan,
The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone).
2011,
Pubmed
De Felice,
Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology.
2014,
Pubmed
Drug Enforcement Administration (DEA), Department of Justice,
Establishment of drug codes for 26 substances. Final rule.
2013,
Pubmed
Eshleman,
Substituted methcathinones differ in transporter and receptor interactions.
2013,
Pubmed
Fantegrossi,
In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.
2013,
Pubmed
Gatch,
Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones.
2013,
Pubmed
Gil,
Analysis of 4-MEC in biological and non-biological material--three case reports.
2013,
Pubmed
Gobbi,
N,N-dimethyl-thioamphetamine and methyl-thioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant in vitro efficacy for the induction of transporter-mediated 5-HT release and currents.
2008,
Pubmed
,
Xenbase
Hadlock,
4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.
2011,
Pubmed
Hofmaier,
Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters.
2014,
Pubmed
Hou,
Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations.
2011,
Pubmed
Jones,
Development and validation of a genetic algorithm for flexible docking.
1997,
Pubmed
Kehr,
Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats.
2011,
Pubmed
Kolanos,
"Deconstruction" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter.
2013,
Pubmed
,
Xenbase
Kristensen,
SLC6 neurotransmitter transporters: structure, function, and regulation.
2011,
Pubmed
Leffler,
The analytical investigation of synthetic street drugs containing cathinone analogs.
2014,
Pubmed
Lewin,
Emergence and properties of spice and bath salts: a medicinal chemistry perspective.
2014,
Pubmed
López-Arnau,
Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone.
2012,
Pubmed
Marinetti,
Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results.
2013,
Pubmed
Marusich,
Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice.
2012,
Pubmed
Marusich,
Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).
2014,
Pubmed
Meltzer,
1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.
2006,
Pubmed
Penmatsa,
X-ray structure of dopamine transporter elucidates antidepressant mechanism.
2013,
Pubmed
Rojek,
Cathinones derivatives-related deaths as exemplified by two fatal cases involving methcathinone with 4-methylmethcathinone and 4-methylethcathinone.
2014,
Pubmed
Rosenbaum,
Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.
2012,
Pubmed
Rothman,
Monoamine transporters and psychostimulant drugs.
2003,
Pubmed
Sali,
Evaluation of comparative protein modeling by MODELLER.
1995,
Pubmed
Scholze,
Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter.
2000,
Pubmed
Seddik,
Probing the Selectivity of Monoamine Transporter Substrates by Means of Molecular Modeling.
2013,
Pubmed
Simmler,
Pharmacological characterization of designer cathinones in vitro.
2013,
Pubmed
Simmler,
Monoamine transporter and receptor interaction profiles of a new series of designer cathinones.
2014,
Pubmed
Sitte,
Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter.
1998,
Pubmed
Sitte,
The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters--why amphetamines take two to tango.
2010,
Pubmed
Sonders,
Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants.
1997,
Pubmed
,
Xenbase
Spiller,
Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.
2011,
Pubmed
Springer,
Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry.
2002,
Pubmed
Springer,
Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry.
2003,
Pubmed
Steinkellner,
The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.
2011,
Pubmed
Tatsumi,
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
1997,
Pubmed
Thompson,
Multiple sequence alignment using ClustalW and ClustalX.
2002,
Pubmed
Wang,
Structural basis for action by diverse antidepressants on biogenic amine transporters.
2013,
Pubmed
Watterson,
Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV).
2014,
Pubmed
Wilhelm,
Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins.
2014,
Pubmed
Wright,
Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats.
2012,
Pubmed
Yu,
Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters.
2000,
Pubmed
Zolkowska,
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
2009,
Pubmed
